Targeting of the prostate-specific membrane antigen (PSMA) with [177Lu]Lu-PSMA therapy evolved as a promising strategy for the treatment of metastasized castration-resistant prostate cancer, which is one of the main worldwide causes of death in men (1). Here, FOLH1 is linked to prostate carcinoma.